Equity
€84,109 from €161,390 in 2021
Equity fell by 48% in 4 years.
Smart Pharma
Lifetime
11 annual accounts with figures on one time axispeak €124,009 (2020)
€55,858▼ 13.6%
lowest -€38,424 (2024)
-€37,265▲ €1,159
peak €161,390 (2021)
€84,109▼ 30.7%
€399,368▲ 8.2%
peak 1.1 FTE (2025)
1.1 FTE▲ 10.0%
Board4 names since 2015
1 director
Owners2 names in the annual accounts
100%
Documentsfilings and deeds
24-08-202624 days late
2025abbreviated format
Gross margin from €64,649 to €55,858Loss of €37,265Staff from 1 FTE to 1.1 FTEEquity from €121,374 to €84,109Cash from €9,880 to €15,179
Key points
from the 2025 annual accountsLosses
-€77,281 in four years
Every financial year from 2022 to 2025 closed with a loss. 2024 was the heaviest.
Debts
€399,368 83% of the balance sheet
Financial debts 40%Suppliers 24%Taxes and wages 4%Other 31%
Of this, €236,451 falls due within a year.
Staff
2 employees on 31-12-2025
In 2025, 3 people joined and 2 left.
Filings
11 annual accounts since 2015
Three of the last ten came late. The 2022 accounts came latest: 30 days after the end of the period.
Position in the sector
-€37,265
Lower net result than 87% of companies in retail trade. Sector median €37,973 · 13,245 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,167 companies had the same profile as Smart Pharma has now. Each dot stands for 6 companies, two years later.
94.0%
were still trading
3.1%
stopped another way
2.5%
went bankrupt
Another 0.4% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,167 companies, not a prediction for Smart Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 01-04-2023
- 100%score equity €7,826 (2025) · 30-06-2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0588980436
1 director appointed, 1 resignation
Resignation: · Permanent representatives: and · Appointment: · General meeting of 31-03-2023 · Gazette deed
1 manager appointed, 2 resignations
Resignations: (manager) and (manager) · Appointment: (manager) · Permanent representative: · General meeting of 31-08-2018 · Gazette deed
Incorporation
Founders: and · Founding capital of €18,600, 100 shares, €6,200 paid up · Appointments: (manager) and (manager) · published on 02-02-2015 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Smart Pharma Ixelles | €483,477 | €55,858 | 17.4% | 1.1 |
| PHARMACIE DALNE Schaerbeek | €419,660 | €93,420 | 5.0% | 0.8 |
| APOTHEEK PEETERS Tienen | €391,521 | €83,634 | 74.2% | 1.3 |
| APOTHEEK TOMBAL Lier | €396,952 | €97,644 | 76.7% | 1.1 |
| APOTHEEK ROZEMAAI Antwerp | €307,785 | €58,047 | 43.5% | 1.3 |
| DETIPHAR Colfontaine | €356,249 | €88,159 | 66.5% | 1 |
| AZ.PHARMABEL Schaerbeek | €479,564 | €69,439 | 21.0% | - |
These companies have the same main activity as Smart Pharma: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €308,000 and €480,000, founded between 2010 and 2013.
Official details
Source: KBO- Status
- Active since 29-01-2015Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 10 others
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.241.404.5361050 Ixelles, since 29-01-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 26-11-2025
Annual accounts 2025
- ≈ €270,000estimated
- €483,477▼ 1.5%
- Employeeson 31-12-2025
- 2▲ 100%
- Filing
- Filed on 24-08-2026
Insights on Smart Pharma
Smart Pharma files the abbreviated format. That format states no turnover. The gross margin fell from €61,767 in 2015 to €55,858 in 2025.
holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Smart Pharma
- What is the company number of Smart Pharma?
- The company number of Smart Pharma is 0588.980.436. The VAT number is the same number with BE in front: BE 0588.980.436.
- Where is Smart Pharma based?
- The registered office is at Waterloose Steenweg 606A, 1050 Ixelles.Company details
- What does Smart Pharma do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of Smart Pharma?
- Smart Pharma is a private limited company (pre-2019) (BVBA).
- When was Smart Pharma founded?
- Smart Pharma was founded on 29-01-2015.
- Is Smart Pharma still active?
- Yes, Smart Pharma is an active enterprise in the KBO register.
- How many employees does Smart Pharma have?
- Smart Pharma had an average of 1.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does Smart Pharma fall under?
- In its 2025 annual accounts, Smart Pharma states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of Smart Pharma?
- The turnover in financial year 2025 is ≈ €270,000. This figure is estimated from the gross margin of €55,858 and 76 comparable companies (NACE 477). It probably lies between €130,000 and €390,000.
- Is Smart Pharma profitable?
- In financial year 2025, Smart Pharma made a loss of €37,265.
- Where can I find the annual accounts of Smart Pharma?
- Smart Pharma filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Smart Pharma due?
- Smart Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.